Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Nat Commun
Main Authors: Oellerich, Thomas, Schneider, Constanze, Thomas, Dominique, Knecht, Kirsten M., Buzovetsky, Olga, Kaderali, Lars, Schliemann, Christoph, Bohnenberger, Hanibal, Angenendt, Linus, Hartmann, Wolfgang, Wardelmann, Eva, Rothenburger, Tamara, Mohr, Sebastian, Scheich, Sebastian, Comoglio, Federico, Wilke, Anne, Ströbel, Philipp, Serve, Hubert, Michaelis, Martin, Ferreirós, Nerea, Geisslinger, Gerd, Xiong, Yong, Keppler, Oliver T., Cinatl, Jindrich
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6677770/
https://ncbi.nlm.nih.gov/pubmed/31375673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-11413-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים